UVM Reference Number: C614
Summary:
Current treatments for allergic diseases such as asthma, atopic eczema and psoriasis are still not effective for 10% of the millions of patients worldwide with these diseases. Dual oxidase (DUOX1) is a member of the NADPH oxidase family and is a critical mediator of innate immune response to allergens. Several thiol-reactive electrophiles have been identified that inhibit airway allergen response via DUOX1 inhibition and based on this work, selective peptide-based inhibitors have been designed to provide a novel approach to treat patients with allergic asthma or skin disorders, which will serve as a base for small molecule design as well.
Applications:
- Asthma, atopic eczema and psoriasis.
Advantages:
- Novel targeting of a central immune mediator.
- Selective inhibition via covalent cysteine binding.
- Peptide and small molecule targeting.
References:
Acrolein and thiol-reactive electrophiles suppress allergen-induced innate airway epithelial responses by inhibition of DUOX1 and EGFR, Danyal et al. PMC5130541
Dual oxidase: a novel therapeutic target in allergic disease, van der Vliet et al. PMC5900994
Opportunity:
- Looking for research and development partners and licensing opportunities.
Patents:
Seeking:
- Licensing
- Development partner
